CEO Dr. Mark Day of Bioasis Technologies Inc. (OTCQB: BIOAF), joins Stock Day to give details on developing xB3 for treatment of brain cancer and neurodegenerative disease.

OTCQB: BIOAF # biopharmaceutical company developing xB3 # proprietary platform technology # disease-modifying treatments # Alzheimer’s and Huntington’s # blood-brain barrier (BBB) # brain cancers and neurodegenerative diseases # Canada # Glioblastoma # Parkinson’s # treatment of CNS disorders # Vancouver